Etoposide

MALT Lymphoma

Fred Hutchinson Cancer CenterSmall moleculePhase 2Dormant

BB

70/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 63/ 100
Competitive Position: 81/ 100

Competitive context

33 Active assets in the MALT Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Cyclophosphamide SWOG Cancer Research Network	Phase 2	BBB
Dexasone Izidore Lossos, MD	Phase 2	BBB
Rituximab City of Hope Medical Center	Phase 3	BBB
Vincristine Sulfate SWOG Cancer Research Network	Phase 2	BB
Fludarabine UNC Lineberger Comprehensive Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Etoposide is also rated in:

acute megakaryoblastic leukemiaDormant

BBB

Indicative · Phase 3

79 / 100

acute monocytic leukemiaDormant

BBB

Indicative · Phase 3

79 / 100

acute myeloblastic leukemia with maturationDormant

BBB

Indicative · Phase 3

79 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.